In an effort to bring U.S. prescription drug pricing into line with that of other wealthy countries, pharmaceutical giant AstraZeneca today signed a historic agreement with the US government. After a similar agreement with Pfizer last month, AstraZeneca is now the second major pharmaceutical company to adopt the administration’s “Most-Favored-Nation” (MFN) drug pricing model. The arrangement was announced at the White House by CEO Pascal Soriot alongside President Donald J. Trump.
The firm pledged a significant investment in U.S. manufacturing and infrastructure and committed to a number of initiatives that will result in real cost savings for millions of Americans.
$50 Billion Investment and Tariff Relief
AstraZeneca made a major commitment to American jobs and innovation in exchange for granting the administration’s pricing requirements and securing certainty against potential tariffs.
Over the next five years, the business has committed to investing $50 billion in research and development (R&D) and pharmaceutical manufacturing in the United States. The goal of this initiative is to completely outsource the production of its medications, guaranteeing that every AstraZeneca medication marketed in the United States is “Made in America.”
This drive for indigenous manufacturing is supported by:
- The beginning of work on the company’s biggest production facility investment to date in Virginia, which will serve the company’s cancer and metabolic pipelines.
- The planned growth of a Coppell, Texas, manufacturing plant.
Direct Patient Savings
Improving the U.S. healthcare system’s access to worldwide medicine prices is the main goal of the deal. Several significant price efforts have been agreed to by AstraZeneca:
Exdensur (depemokimab) China approval: A Paradigm Shift in Severe Asthma Treatment
GSK has secured the Exdensur depemokimab China approval from the NMPA, introducing the first respiratory biologic with a twice-yearly dosing regimen for patients with severe […]
- Deep Direct-to-Consumer (DTC) Discounts: AstraZeneca will provide up to 80% off list prices in DTC sales to qualified individuals who have prescriptions for chronic illnesses.
- Discounted Key Medicines: The deal emphasizes substantial savings on a number of popular, targeted medications. Inhalers for respiratory conditions will be significantly cheaper for patients buying directly.
- The COPD treatment BREZTRI AEROSPHERE will be offered at a 98% reduction off the sale price.
- The asthma medication AIRSUPRA will be offered at a 96% reduction off the sale price.
- TrumpRx.gov Participation: AstraZeneca will take part in the forthcoming TrumpRx.gov direct purchasing platform, which will allow patients to buy medications directly from the corporation at a discounted cash price.
Last Modified:
